SCHEMBL5540755

SCHEMBL5540755

O=[C]CCN1CCN(CC(=O)Nc2ccc(Cl)c(Cl)c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.61
MAPT P10636 5/20 0.60
LMNA P02545 3/20 0.60
GAA P10253 2/20 0.60
HTT P42858 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
HPGD P15428 1/20 0.54
ALDH1A1 P00352 4/20 0.53
NPSR1 Q6W5P4 1/20 0.53
POLB P06746 2/20 0.52
KMT2A Q03164 5/20 0.51
MEN1 O00255 4/20 0.49
MAPK1 P28482 1/20 0.49
CYP3A4 P08684 2/20 0.49
TP53 P04637 2/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
TSHR P16473 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540761 0.82 TDP1 (0.61) TDP1MAPTLMNAGAAHTT
SCHEMBL5536902 0.80 ALDH1A1 (0.70) LMNAGAASMN1; SMN2ALDH1A1NPSR1
SCHEMBL5537720 0.78 CA1 (0.56) MAPTLMNAALDH1A1POLBKMT2A
SCHEMBL5539236 0.75 KMT2A (0.73) LMNAGAASMN1; SMN2HPGDALDH1A1
SCHEMBL4007645 0.73 ALDH1A1 (0.78) MAPTLMNAGAASMN1; SMN2ALDH1A1
SCHEMBL12139490 0.72 HPGD (0.71) TDP1LMNAHTTSMN1; SMN2HPGD
SCHEMBL5542063 0.72 ANXA2 (0.58) GAAHTTSMN1; SMN2HPGDALDH1A1
SCHEMBL12139485 0.71 HPGD (0.74) TDP1MAPTLMNAHTTSMN1; SMN2
SCHEMBL5541851 0.70 ALDH1A1 (0.43) LMNAGAAALDH1A1POLBKMT2A
SCHEMBL1943276 0.70 MEN1 (0.74) MAPTHTTHPGDALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TDP1 4666/4885MAPT 4117/4885LMNA 4152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.